Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Cameco Corporation: Initiation of Research Coverage

    William Blair initiated research coverage of Cameco Corporation (CCJ $120.27), a global leader in uranium mining, refining, and conversion.

    Read more

  • Biotech Breakthroughs: Gene Editing Moves Beyond the Hype

    In this episode of Biotech Breakthroughs, Matt Phipps, Ph.D., group head of biotech research, and William Blair biotech analyst Myles Minter, Ph.D., discuss lessons from the first approved ex‑vivo product and highlight key 2026 catalysts across CRISPR, base editing, RNA editing, and DNA writing.

    Listen to the podcast

  • Economics Weekly: Bonds Protect Against Growth Shocks, Not Inflation Shocks

    In this Economics Weekly Richard de Chazal argues that the stock-to-bond correlation has moved from negative to positive and explains what that means for investors.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures